VIJAYA DIAGNOSTIC CENTRE

February 4, 2022

To,
Listing Department
National Stock Exchange of India Limited,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Company Code No. VIJAYA

To,
The Corporate Relations Department
BSE Limited,
Phiroz Jeejeebhoy Towers,
25th Floor, Dalal Street
Mumbai- 400 001
Company Code No. 543350

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on February 4, 2022.

The Board of Directors of the Company at its meeting held on February 4, 2022 has inter alia considered and approved the following:-

1. Unaudited standalone and consolidated financial results of the Company for the quarter ended December 31, 2021.
   The copy of the aforesaid un-audited financial results of the Company together with Limited Review Report(s) of Statutory Auditor is enclosed herewith as Annexure I.

2. Authorized the Key Managerial Personnel (KMP) of the Company to determine the materiality of events as prescribed under Regulation 30 (5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015;
   Details of the KMP are enclosed as Annexure II.

The Board meeting commenced at 3.55 p.m. and concluded at 5.05 p.m.

Kindly take the same on record.
Thanking you,

For Vijaya Diagnostic Centre Limited

K. Anusha

Anusha Kanumuru
Company Secretary

VIJAYA DIAGNOSTIC CENTRE LIMITED

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited Review Report on unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

   Attention is drawn to the fact that the figures for the corresponding quarter ended 31 December 2020 and the corresponding period from 01 April 2020 to 31 December 2020, as reported in these unaudited consolidated financial results have been approved by the Parent's Board of Directors, but have not been subjected to review since the requirement of submission of quarterly consolidated financial results is applicable on listing of equity shares of the Company during the quarter ended 30 September 2021.

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

   a. Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') **(Parent)**

   Subsidiaries
   b. Medinova Diagnostic Services Limited
   c. VDC Diagnostics (Karnataka) LLP
   d. Doctors Lab Medical Services Private Limited
   e. Medinova Millenium MRI Services LLP
   f. Namrata Diagnostic Centre Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of 2 subsidiaries included in the Statement, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. 260.73 lakhs and Rs. 1,050.70 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 39.56 lakhs and Rs. 201.10 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 39.34 lakhs and Rs. 200.44 lakhs, for the quarter ended 31 December 2021 and for the period from 01 April 2021 to 31 December 2021 respectively, as considered in the unaudited consolidated financial results. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial results of 3 Subsidiaries which have not been reviewed, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. Nil and Rs. Nil, total net profit after tax (before consolidation adjustments) of Rs. 3.62 lakhs and Rs. 13.83 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 3.62 lakhs and Rs. 13.83 lakhs, for the quarter ended 31 December 2021 and for the period from 01 April 2021 to 31 December 2021 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial results are not material to the Group.

   Our conclusion is not modified in respect of this matter.

For **B S R & Associates LLP**
Chartered Accountants
Firm's Registration No.:116231W/W-100024

Amit Kumar Bajaj
Partner
Membership No.: 218685
UDIN:22218685AAIZAC7136

Hyderabad
04 February 2022

VIJAYA DIAGNOSTIC CENTRE

Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Center Private Limited')
CIN: U85195TG2002PLC039075
Regd. Office: 3-6-16 & 17, Street No. 19, Himayatnagar, Hyderabad-500029, Telangana, India
Corporate Office: No.6-3-883/F, FPA Building, Near Rajiv Gandhi Statute Lane Adjacent to Topaz Building, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended 31 December 2021

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	(a) Revenue from operations	11,077.58	11,270.73	9,988.30	34,616.96	26,473.75	37,674.57
	(b) Other income	320.15	315.45	299.10	963.97	763.86	1,184.64
	Total income	**11,397.73**	**11,586.18**	**10,287.40**	**35,580.93**	**27,237.61**	**38,859.21**
2	**Expenses**						
	(a) Cost of materials consumed	1,629.89	1,623.85	1,397.77	5,362.15	4,082.97	5,709.45
	(b) Employee benefits expense	1,822.15	1,709.50	1,517.65	5,146.20	4,225.89	5,743.33
	(c) Finance costs	417.58	393.68	360.12	1,211.52	1,177.69	1,524.60
	(d) Depreciation and amortisation expense	1,300.72	1,247.74	1,250.34	3,740.55	3,790.22	5,045.14
	(e) Other expenses	2,842.57	2,822.57	2,430.37	8,525.25	7,009.14	9,624.30
	Total expenses	**8,012.91**	**7,797.34**	**6,956.25**	**23,985.67**	**20,285.91**	**27,646.82**
3	**Profit Before Tax (PBT) [1 - 2]**	**3,384.82**	**3,788.84**	**3,331.15**	**11,595.26**	**6,951.70**	**11,212.39**
4	**Tax expense**						
	(a) Current tax	881.51	1,065.82	855.72	3,121.43	2,052.42	3,174.49
	(b) Deferred tax, net	(45.26)	(76.67)	(30.82)	(207.04)	(447.08)	(453.17)
	(c) Tax pertaining earlier years	2.47	-	1.52	2.47	1.95	(21.58)
	Total tax expense	**838.72**	**989.15**	**826.42**	**2,916.86**	**1,607.29**	**2,699.74**
5	**Profit for the period [3-4]**	**2,546.10**	**2,799.69**	**2,504.73**	**8,678.40**	**5,344.41**	**8,512.65**
6	**Other comprehensive income**						
	Items that will not be reclassified to profit or loss						
	(a) Remeasurement of the defined benefit obligations	(2.77)	(2.77)	9.71	(8.31)	(5.04)	(0.16)
	(b) Income-tax relating to above item	0.64	0.64	(2.44)	1.92	1.27	(1.17)
	Other comprehensive income for the period (net of tax)	**(2.13)**	**(2.13)**	**7.27**	**(6.39)**	**(3.77)**	**(1.33)**
7	**Total comprehensive income for the period [5+6]**	**2,543.97**	**2,797.56**	**2,512.00**	**8,672.01**	**5,340.64**	**8,511.32**
	Profit for the period attributable to:						
	Owners of the Company	2,528.65	2,771.19	2,472.76	8,596.81	5,306.20	8,447.82
	Non controlling interests	17.45	28.50	31.97	81.59	38.21	64.83
	Other comprehensive income attributable to:						
	Owners of the Company	(2.05)	(2.04)	7.27	(6.14)	(3.77)	0.49
	Non controlling interests	(0.08)	(0.09)	-	(0.25)	-	(1.82)
	Total comprehensive income attributable to:						
	Owners of the Company	2,526.60	2,769.15	2,480.03	8,590.67	5,302.43	8,448.31
	Non controlling interests	17.37	28.41	31.97	81.34	38.21	63.01
8	**Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 5)**	1,019.66	1,019.66	453.19	1,019.66	453.19	453.19
9	**Other equity**						35,447.45
10	**Earnings per equity share (face value of Rs. 1 each fully paid up) (non annualized for quarter and nine months ended) (Refer Note 5)**						
	- Basic (in Rs.)	2.48	2.72	2.43	8.43	5.20	8.28
	- Diluted (in Rs.)	2.46	2.70	2.42	8.37	5.20	8.28

B S R & Associates LLP CHARTERED ACCOUNTANTS

VIJAYA DIAGNOSTIC CENTRE LIMITED

Notes:

1. The above consolidated financial results of Vijaya Diagnostic Centre Limited (formerly known as 'Vijaya Diagnostic Centre Private Limited') ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The Company has completed its Initial Public Offer ('IPO') and listed its equity shares on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE') on 14 September 2021. Accordingly, the figures for the quarter and the nine months ended 31 December 2020 as reported in these financial results were neither reviewed nor subject to audit, however, the management has exercised necessary diligence to ensure that the financial results for these periods provide a true and fair view of the Group's affairs. The historical annual financial statements of the company and it's subsidiaries are available on its website at www.vijayadiagnostic.com.

3. The above consolidated financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 4th February 2022. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended 31 December 2021. An unmodified review opinion has been issued by them thereon.

4. The Group's operations fall within a single business segment "Diagnostic services".

5. On 22 March 2021, the equity shares of the Company having the face value of Rs. 10 each were subdivided into 10 equity shares having a face value of Re. 1 each. Accordingly, 4,531,819 equity shares of face value of Rs. 10 each were subdivided into 45,318,190 equity shares of face value of Re. 1 each. The Company issued bonus shares on 27 May 2021 in proportion of five new equity shares of Re. 1 each for every four existing equity shares of Re. 1 each, resulting in total fully paid-up equity shares of 101,965,926 of Re. 1 each. The basic / diluted earnings per share have been adjusted towards this subdivision and bonus issue of shares for all the periods presented.

6. The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Group is closely monitoring the impact of the pandemic on all aspects of it's business, including how it will impact its employees, vendors and business partners. The Group based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact on the financial results. Based on the current estimates, the Group expects to fully recover the carrying amount of assets, and does not foresee any material adverse impact on its operations. As the outbreak continues to evolve, the Group will continue to closely monitor any material changes to future economic condition.

7. The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

8. Previous period figures have been regrouped / rearranged wherever considered necessary.

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited
(Formerly known as 'Vijaya Diagnostic Center Private Limited')

K. Sunil Chandra
Executive Director
DIN Number: 01409332

Place: Hyderabad
Date: 04 February 2022

B S R & Associates LLP • CHARTERED ACCOUNTANTS •

VIJAYA DIAGNOSTIC CENTRE LIMITED

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited Review Report on unaudited standalone financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited')

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') ("the Company") for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 ("the Statement").

   Attention is drawn to the fact that the figures for the corresponding quarter ended 31 December 2020 and the corresponding period from 01 April 2020 to 31 December 2020, as reported in these unaudited standalone financial results have been approved by the Company's Board of Directors, but have not been subjected to review since the requirement of submission of quarterly standalone financial results is applicable on listing of equity shares of the Company during the quarter ended 30 September 2021.

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above , nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Associates LLP**
Chartered Accountants
Firm's Registration No.:116231W/W-100024

Amit Kumar Bajaj
Partner
Membership No.: 218685
UDIN:22218685AAIZTG5960

Hyderabad
04 February 2022

VIJAYA DIAGNOSTIC CENTRE

Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Center Private Limited')
CIN: U85195TG2002PLC039075
Regd. Office: 3-6-16 & 17, Street No. 19, Himayatnagar, Hyderabad-500029, Telangana, India
Corporate Office: No.6-3-883/F, FPA Building, Near Rajiv Gandhi Statute Lane Adjacent to Topaz Building, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Standalone Financial Results for the quarter and nine months ended 31 December 2021

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	(a) Revenue from operations	10,830.96	10,949.82	9,692.77	33,713.88	25,781.46	36,731.59
	(b) Other income	319.59	315.68	282.90	960.54	737.33	1,083.12
	Total income	**11,150.55**	**11,265.50**	**9,975.67**	**34,674.42**	**26,518.79**	**37,814.71**
2	**Expenses**						
	(a) Cost of materials consumed	1,572.40	1,523.72	1,343.31	5,148.09	3,970.76	5,551.05
	(b) Employee benefits expense	1,771.86	1,659.28	1,471.66	4,996.70	4,095.62	5,570.53
	(c) Finance costs	414.05	389.85	351.68	1,195.39	1,145.78	1,481.23
	(d) Depreciation and amortisation expense	1,286.77	1,233.89	1,231.62	3,699.19	3,736.32	4,972.96
	(e) Other expenses	2,767.61	2,741.38	2,341.40	8,289.84	6,770.92	9,280.32
	Total expenses	**7,812.69**	**7,548.12**	**6,739.67**	**23,329.21**	**19,719.40**	**26,856.09**
3	**Profit before tax (PBT) [1-2]**	**3,337.86**	**3,717.38**	**3,235.99**	**11,345.21**	**6,799.39**	**10,958.62**
4	**Tax expense**						
	(a) Current tax	872.00	1,054.00	854.00	3,066.00	2,050.00	3,150.00
	(b) Deferred tax	(37.40)	(69.16)	(30.81)	(184.28)	(447.08)	(450.00)
	(c) Tax pertaining to earlier years	-	-	-	-	-	(23.53)
	Total tax expense	**834.60**	**984.84**	**823.19**	**2,881.72**	**1,602.92**	**2,676.47**
5	**Profit for the year [3 - 4]**	**2,503.26**	**2,732.54**	**2,412.80**	**8,463.49**	**5,196.47**	**8,282.15**
6	**Other comprehensive income**						
	Items that will not be reclassified to profit or loss						
	(a) Remeasurement of defined benefit obligations	(2.55)	(2.55)	9.71	(7.65)	(5.04)	4.66
	(b) Income-tax relating to above item	0.64	0.64	(2.44)	1.92	1.27	(1.17)
	Other comprehensive income for the year (net of tax)	**(1.91)**	**(1.91)**	**7.27**	**(5.73)**	**(3.77)**	**3.49**
7	**Total comprehensive income for the period [5 + 6]**	**2,501.35**	**2,730.63**	**2,420.07**	**8,457.76**	**5,192.70**	**8,285.64**
8	**Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 5)**	1,019.66	1,019.66	453.19	1,019.66	453.19	453.19
9	**Other equity**						35,601.72
10	**Earnings per equity share (face value of Rs. 1 each, fully paid) (non annualized for quarter and nine months ended) (Refer Note 5)**						
	- Basic (in Rs.)	2.45	2.68	2.37	8.30	5.10	8.12
	- Diluted (in Rs.)	2.44	2.66	2.37	8.24	5.09	8.12

B S R & Associates LLP • CHARTERED ACCOUNTANTS •

VIJAYA DIAGNOSTIC CENTRE LIMITED

Notes:

1. The above standalone financial results of Vijaya Diagnostic Centre Limited (Formerly known as 'Vijaya Diagnostic Centre Private Limited') ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The Company has completed its Initial Public Offer ('IPO') and listed its equity shares on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE') on 14 September 2021. Accordingly, the figures for the quarter and the nine months ended 31 December 2020 as reported in these financial results were neither reviewed nor subject to audit, however, the management has exercised necessary diligence to ensure that the financial results for these periods provide a true and fair view of the Company's affairs. The historical annual financial statements of the company are available on its website at www.vijayadiagnostic.com.

3. The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 4th February 2022. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended 31 December 2021. An unmodified review opinion has been issued by them thereon.

4. The Company's operations fall within a single business segment "Diagnostic services".

5. On 22 March 2021, the Equity shares of the Company having the face value of Rs. 10 each were subdivided into 10 equity shares having a face value of Re. 1 each. Accordingly, 4,531,819 equity shares of face value of Rs. 10 each were subdivided into 45,318,190 equity shares of face value of Re. 1 each. The Company issued bonus shares on 27 May 2021 in proportion of five new equity shares of Re. 1 each for every four existing equity shares of Re. 1 each, resulting in total fully paid-up equity shares of 101,965,926 of Re. 1 each. The basic / diluted earnings per share have been adjusted towards this subdivision and bonus issue of shares for all the periods presented.

6. The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Company is closely monitoring the impact of the pandemic on all aspects of it's business, including how it will impact its employees, vendors and business partners. The Company based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact on the financial results. Based on the current estimates, the Company expects to fully recover the carrying amount of assets, and does not foresee any material adverse impact on its operations. As the outbreak continues to evolve, the Company will continue to closely monitor any material changes to future economic condition.

7. The results of the Company are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

8. Previous period figures have been regrouped / rearranged wherever considered necessary.

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited
(Formerly known as 'Vijaya Diagnostic Center Private Limited')

K. Sunil Chandra
Executive Director
DIN Number: 01409332

Place: Hyderabad
Date: 04 February 2022

B S R & Associates LLP • CHARTERED ACCOUNTANTS •

VIJAYA DIAGNOSTIC CENTRE LIMITED

VIJAYA DIAGNOSTIC CENTRE

Annexure II

Details of Company's KMP authorised to determine the materiality of events.

S.No	Name of the KMP	Designation	Contact Details	Authorisation
1	Mr.K.Sunil Chandra	Executive Director	suneil@vijayadiagnostic.in	Determination of materiality of event(s).
2	Ms.S.Suprita Reddy	Chief Executive Officer	suprita@vijayadiagnostic.in	
3	Mr.Narasimha Raju KA	Chief Financial Officer	narasimharaju@vijayadiagnostic.in	
4	Ms.Anusha K	Company Secretary	anusha.k@vijayadiagnostic.in	Disclosure of such material event(s) to Stock Exchanges

For Vijaya Diagnostic Centre Limited

K. Anusha

Anusha Kanumuru
Company Secretary

VIJAYA DIAGNOSTIC CENTRE LIMITED